Occudo Quantitative Strategies LP Has $175,000 Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Occudo Quantitative Strategies LP boosted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 57.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,737 shares of the company’s stock after purchasing an additional 18,952 shares during the period. Occudo Quantitative Strategies LP’s holdings in Xeris Biopharma were worth $175,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. NewEdge Advisors LLC acquired a new stake in Xeris Biopharma during the 4th quarter valued at $34,000. R Squared Ltd acquired a new stake in Xeris Biopharma during the 4th quarter valued at $42,000. Cibc World Markets Corp acquired a new stake in shares of Xeris Biopharma in the 4th quarter valued at $44,000. Raymond James Financial Inc. acquired a new stake in shares of Xeris Biopharma in the 4th quarter valued at $45,000. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Xeris Biopharma in the 4th quarter valued at $50,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the transaction, the insider now directly owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. The trade was a 2.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 6.47% of the stock is owned by corporate insiders.

Xeris Biopharma Stock Up 1.9%

NASDAQ:XERS opened at $4.88 on Friday. Xeris Biopharma Holdings, Inc. has a 12-month low of $1.86 and a 12-month high of $6.07. The firm has a market capitalization of $763.16 million, a P/E ratio of -10.84 and a beta of 1.10. The stock’s fifty day simple moving average is $4.72 and its 200-day simple moving average is $3.91.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $57.80 million during the quarter, compared to the consensus estimate of $57.61 million. As a group, equities research analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Analysts Set New Price Targets

XERS has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Craig Hallum lifted their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research note on Friday, March 7th. Oppenheimer lifted their target price on Xeris Biopharma from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Friday, May 9th. Jefferies Financial Group reissued a “buy” rating and issued a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Finally, Leerink Partners lifted their target price on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.25.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.